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  ABSTRACT 
 
    For arrhythmia triggers that are secondary to dysfunctional intracellular Ca2+ cycling, 
there are few if any specific agents that target exactly the Ca2+ handling machinery. 
However, in the literature to date, several candidates have been proposed. We review 
here these agents with the idea that in the future these agents or those derived thereof 
will prove invaluable in clinical application. 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
JHRM-D-17-01205R1 Boyden and Smith 
 
 3
   INTRODUCTION    
      Under normal conditions for all cardiac cells, during systole, Ca2+ influx through the 
cardiac calcium channel provides a trigger for the calcium to be released from the 
sarcoplasmic reticulum (SR) through a large SR membrane, ligand operated, ion 
channel called the ryanodine receptor (RYR).  The open probability of the RYR protein is 
increased by the elevation of cytoplasmic Ca2+ concentration [Ca2+]i. Thus, Ca2+ entry 
into the cell produces a small increase of Ca2+ which leads to an opening of the RYR 
and subsequent release of a larger amount of Ca2+ that is stored in the SR.  This 
process is known as calcium induced calcium release (CICR) (Figure 1).  Microscopic 
signals resulting from clusters of RYR openings generate Ca2+ signals called Ca2+ 
sparks. Spatial and temporal summation of action potential evoked Ca2+ sparks 
underlies the global Ca2+ transient which in contractile cells has a familiar rise and decay 
as Ca2+ is released is reuptaken into the SR ready for the next heartbeat. Any remaining 
cytosolic Ca2+ is pumped out of cell by sodium calcium exchanger protein (NCX). Under 
normal conditions, CICR that occurs does not propagate but rather remains controlled by 
L type Ca2+ channel influx.  
 
So what is “Ca2+ leak” if the cell always has spontaneous Ca2+ sparks, 
albeit at low probability? 
      When a cell is “overloaded” with calcium the associated sequestration of Ca2+ by the 
SR can increase SR Ca2+ content to above normal levels, under these circumstances 
the Ca2+ leaks out of the SR in the form of Ca2+ waves. These are local Ca2+ release 
events that trigger a regenerative Ca2+ waves via the CICR process. The Ca2+ wave can 
propagate throughout the cell  and in some cases can trigger a Ca2+ waves in an 
adjacent cell (Figure 2)(see also 1).  It appears that intracellular Ca2+ waves generally 
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occur when the SR Ca2+ content is elevated above a threshold value 2, 3, but other 
changes, such as altered Ca2+ sensitivity of the RyR can induced Ca2+ waves. Some of 
the Ca2+ in the wave is pumped out of the cell by the electrogenic NCX. The resulting 
current depolarizes the membrane (producing a delayed afterdepolarization (DAD) like 
membrane voltage change) and can be sufficient to initiate an action potential. Yet 
synchrony of Ca2+ releases between coupled cells is required for to provide sufficient 
depolarizing current within one region to initiate an arrhythmic action potential in an 
intact ventricle/atrium. The critical number of coupled cells experiencing a DAD is a topic 
of debate and research 4-6. 
 
      SR Ca2+ leak is increased in numerous pathological conditions (eg. Heart failure (HF) 
7;post MI  8, 9). SR Ca2+ leak, if persistent, decreases SR Ca2+ load and as explained 
above can lead to propagating Ca2+ waves and thus DADs (Figure 3). 
      While Ca2+ leak is an operational term, several mechanisms have been proposed to 
explain the altered RYR gating that leads to Ca2+ leak. An increased sensitivity of RYR 
to its ligand cytosolic Ca2+ may be due to enhanced protein kinase A (PKA) and/or 
CaMKII dependent RYR 7 phosphorylation at specific sites 10 11-13. Recent data using 
human tissues favor one idea where Ca2+ handling abnormalities in HF are due to 
excessive CaMKII phosphorylation at a specific RYR residue 14 15. Other factors such as 
the oxidative state could change resulting in direct activation of the RYR protein16. 
Finally others have suggested that RYR gating may be altered when an abundance of 
endogenous proteins that modulate RYR are altered (eg. sorcin, S100A 17, 18).  
     Finally mutations and dysregulation of RYR and other calcium binding proteins have 
been implicated in several gene-based arrhythmias; for example, RYR and CVPT, and 
Calsequestrin(CASQ) and CPVT 19. Mechanisms of these arrhythmias are similar to 
those of acquired diseases above, that is the arrhythmic events are caused by 
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abnormally propagating Ca2+ waves which cause NCX dependent membrane oscillations 
(DADs) and triggered beats (Figures 2,3). 
 
Can Ca2+ leak be Managed? 
      As an antiarrhythmic, we would want an agent to modulate the mishandled Ca2+ so 
Ca2+ does not increase Ca2+ dependent currents to cause depolarization and elicit action 
potentials. If we target the spontaneous Ca2+ releases, then we would reduce the 
initiators of the Ca2+ waves, the delayed afterdepolarizations and thus triggering beats. 
      The arrhythmias mentioned above result when the cell’s SR Ca2+ content is 
increased above a threshold level at which waves are produced.  Recent work suggests 
that a decrease of threshold (due to a sensitization to RYR Ca2+ release) also produces 
Ca2+ waves and DADs. For arrhythmias seen in heart failure the involvement of DADs in 
some ventricular arrhythmias has been shown 20, 21.  However, in heart failure the SR 
Ca2+ content is decreased suggesting that the threshold for Ca2+ release may be lower, 
such that Ca2+ waves would occur at a lower SR Ca2+ content.  This may be a 
consequence of increased leakiness of the RYR during diastole, such that there is 
increased Ca2+ efflux at a given SR Ca2+ content. The exact molecular mechanisms 
responsible for this are controversial 22, but as above, it may be associated with 
increased phosphorylation of the RYR due to PKA or CaM-Kinase 14.   
        An example of the occurrence of DADs in the absence of increased SR Ca2+ 
content is provided by catecholaminergic polymorphic ventricular tachycardia (CPVT).  
This arrhythmia in patients is seen during exercise or other stress.  The similarity of the 
abnormalities in the ECGs to those observed in digitalis toxicity led to the suggestion of 
similarities in an underlying mechanism.  Genetic studies have shown that many CPVT 
patients have a mutation in RYR (eg R4496C) or the intrasarcoplasmic protein CASQ 
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(eg. R33Q).  The current hypothesis is that the mutated protein causes an increased 
leak of Ca2+ from the SR. Thus Ca2+ waves and DADs occur at a lower SR Ca2+ content 
than in controls 23.(Figure 3)     
Therapies for DAD-related arrhythmias 
    
 For these Ca2+ dependent (Ca2+ wave dependent) arrhythmias, the goal of therapy is to 
treat 1) to prevent the DAD from occurring and/or 2) to prevent the DAD from triggering 
an action potential.  
   The latter can potentially be achieved using sodium channel blockers.  A better 
solution, however, would be to remove the underlying DAD directly.  In the case of 
arrhythmias resulting from “calcium overload”, it may be possible to remove the 
underlying “overload”. For example, local anesthetics (eg. flecainide) reduce intracellular 
Na+ concentration as a consequence of decreasing Na+ entry (via inhibition of sodium 
current resulting in reduced excitability). Lowered intracellular Na+ concentration  will act 
via NCX, to decrease intracellular Ca2+ load 24. Antiarrhythmic effects of flecainide have 
been seen in murine models as well as patients with CPVT 25, but the confirmation that 
the cellular basis is linked to intracellular Na+ levels has yet to be made.  
    Recently, the late Na+ current (INa-late) has gained interest since it is modulated in 
disease. A small fraction of cardiac sodium channels carry INa-late. For peak INa, sodium 
channels open quickly and close in a well-defined time and voltage dependent manner. 
INa-late current is formed when sodium channels remain open or reopen for 100s of ms 
after the peak current. 
  In HF and congenital long QT type3,  INa-late is upregulated and provides enhanced Na+ 
influx during the AP 26. This in turn alters Ca2+I which then could be arrhythmogenic 27. 
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    Ranolazine inhibits cardiac INa-late as well as other channels (eg IKr) 28. Some have 
reported it also inhibits RyR directly 29.  It has been reported to have antiarrhythmic 
properties in various animal models (eg HF, 30, 31). In recent clinical trials it was 
demonstrated to reduce arrhythmic events 32, 33 although there appears to be a risk of 
Torsades de Pointes 34. GS-967 is a newer more specific INa-late current inhibitor (lacks 
the IKr blockade seen with Ranolazine) that shows promise as an antiarrhythmic 35, 36. 
      While Na+ channel blockade of the cardiac Na+ channel is considered now to be a 
viable therapy for Ca2+ mediated arrhythmias, new data suggest that selective blockade 
of Neuronal Na+ channels (eg. Nav1.1,Nav1.3 and Nav1.6s etc) in cardiac T-tubules 
using riluzole is anti-arrhythmic 37. This suggests that there is a contribution of Na+ influx 
from overactive neuronal Na+ channels in RYR subcellular regions to more Ca2+ leak 
from SR  (Figure 4). 
           Theoretically, it would be possible to modulate Ca2+ by affecting the membrane 
transports/channels involved in Ca2+ homeostasis.  For example, L type Ca2+ channel 
pore blockers obviously decrease Ca2+ influx and in so doing would be expected to 
eventually reduce SR load, Ca2+i  and diminish force. Thus Ca2+ channel pore blockers 
(eg. Verapamil) will affect intracellular Ca2+ and wave formation but at the expense of 
force generation. An alternative option to drugs acting directly on molecular targets of 
the SR is to modulate sarcolemma Ca2+ influxes that in turn reduce SR Ca2+ load and 
therefore associated Ca2+-leak related abnormalities. As with other targets, the risk 
associated with reduced SR Ca2+ load is that peak systolic Ca2+ will be reduced and 
associated inotropy. Currently accepted medications such as Ca2+ channel blockers and 
beta blockers reduce cardiovascular mortality partially via reduction of Ca+ influx to the 
heart through their effects on the L-type Ca2+ channel. But the relative contribution of SR 
unloading to the overall beneficial effect of these two classes of drugs is difficult to 
assess.  
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 Alternatively, one might target the molecular mechanism involved in the inactivation of 
Ca2+ channel proteins or the Ca2+ dependent processes known to affect Ca2+ channel 
function (eg. CaMKII) or small proteins (eg.Gem) that are known to affect Ca2+ channel 
subunit assembly 38. 
     Phosphorylation/dephosphorylation of the enzyme CaMKII is critical for cardiac 
excitability and function much like its well-known “neighborhood” protein, protein kinase 
A (PKA). Unlike PKA, CaMKII has the ability to become autophosphorylated and this is a 
Ca2+ independent process 39. But like PKA, CaMKII activity is linked to the function of 
several intracellular cardiac proteins, for example, the L type Ca2+ channel 40 and RYR 
41
. Thus targeting inhibition of this enzyme to alter function of regulated proteins to 
ameliorate Ca2+ wave function and resulting DADs is a goal of both academia and 
industry 42.  
   At this time, only three tools are available.  KN-93 (and its inactive analog KN-62) are 
used frequently in experimental studies to illustrate the role of CaMKII in cardiac cell 
function. KN-93 does inhibit activation of CaMKII but not its autophosphorylation activity. 
But CaMKII inhibition prevents catecholamine induced VTs in CPVT mice 43 and recently 
has proven useful on atrial arrhythmias secondary to Ca2+ leak 44. 
   However, KN93 affects L type Ca 2+ channel function 45 as well as some K+ channel 
function 46. Experimentalists have also used autocamtide-3 inhibitor (AC3-1)  peptides 
that inhibit CaMKII selectively over PKA, PKC 47. AC3-1 is also a potent PKD inhibitor. 
These peptides remain as tools. There has also been a recent emergence of 
pharmacologically active agents designed after small endogenous proteins that inhibit 
CamKII, such as CaMKIIN 48 and CaMKIINide 49. Work continues to delineate how these 
inhibitors affect cardiac function.  
 
Direct modulation of SR leak via actions on RYR channel  
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Designing drugs to bind to RYR directly to reduce the Ca2+ sensitivity of the channel is 
thought to be a valid anti-arrhythmic strategy, but no compounds to date have been 
approved for clinical use purely on this mechanism. While many drugs designed for 
other purposes have been found to alter RYR Ca2+ sensitivity, these have been used as 
tools to investigate the effects of drug-induced modulation of RYR. The anesthetics such 
as tetracaine, which reduces surface membrane excitability via Na+ channel inhibition is 
also known to reduce the sensitivity of Ca2+ induced SR Ca2+ release via a direct action 
on RYR 50. Studies have shown tetracaine substantially reduces the frequency of both 
Ca2+ sparks and spontaneous Ca2+ waves 51 but this effect is accompanied by an 
increased quantity of Ca2+ released from the SR at each spontaneous event (increased 
leak). Derivatives of tetracaine that block RyR appear to inhibit SR Ca2+ leak and prevent 
CPVT arrhythmias in mice 52.  Caffeine, a compound known to increase the Ca2+ 
sensitivity of RYR will increase the frequency of sparks and Ca2+ waves and each 
release event is smaller 53. Interestingly, while these two compounds dramatically affect 
spontaneous Ca2+ release in different ways, the effect on systolic Ca2+ release (in the 
steady-state condition) is undetectable due to an autoregulatory mechanism involving 
Ca2+ influx via the L-type and Ca+ extrusion mainly via NCX 27. Caffeine is known to 
increase ventricular premature beats in normal hearts via its ability to increase the 
incidence of spontaneous Ca2+ waves and thus generate a spontaneous diastolic 
depolarization which generates triggers the extra systole. Many aspects of this 
explanation still require clarification.  
 Drugs have been identified that have an almost exclusive effect on the RYR protein 
complex to reduce Ca2+ sensitivity.  
     The first drug candidate to emerge was the benzodiazepine derivative variously 
known as JTV519/K201. This molecule is similar in structure to L-type Ca2+ channel 
blockers, but was selected for its ability to reduce the effects of intracellular Ca2+ 
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overload 54. Subsequent work suggested that the drug’s mechanism was to bind to RYR 
and mimic the binding of the regulatory protein FK506 binding protein (FKBP12.6) 55. 
FKBP12.6 is thought to bind to RYR and chronically reduce Ca2+ efflux through RYR. As 
part of the beta-adrenergic response, A-kinase mediated phosphorylation may alter the 
Ca2+ sensitivity of RYR via reduced binding of FKBP12.6. In HF, the associated altered 
status of the adrenergic signaling pathway in cardiac muscle is thought to result in hyper 
phosphorylation of RYR, reduced FKBP12.6 binding and thereby increase RYR-
mediated Ca2+ leak from the SR, i.e. acting in an analogous way to caffeine 56. These 
changes are thought to be responsible for the failing myocardium being more prone to 
DADs and subsequent pro-arrhythmic VPCs. In support of  this, JTV519 improved 
outcome in an animal model of HF 57.  JTV519/K201 reduces Ca+ efflux via RYR at 
concentrations that allow reasonable specificity to RYR and appears to have an action in 
the absence of activation of the A-kinase pathway 58.  Therefore, regardless of the 
mechanism, the drug has the possibility to act via RYR as an antiarrhythmic agent on 
myocardium prone to arrhythmias due to dysfunctional RYR, e.g. Purkinje cells that 
survive in the infarcted heart 8 (Figure 5). An alternative structure thought to be an even 
more potent inhibitor of RYR is variously known as S107 or RyCal 10, 59, 60. Others are 
currently being sought. 
Dantrolene and dantrolene-like compounds while showing no effect on normal RyR 
function, inhibits Ca2+ leak in cells from failing hearts by promoting a stable RyR 
conformational state 61-63. 
 
Action on other targets that may aid anti-arrhythmic effects: One feature of small 
molecules is a lack of specificity that may benefit or counteract their ability to suppress 
spontaneous Ca2+ release. For example, JTV519/K201 was found to inhibit SERCA 
activity by a small amount (~10%) at drug levels that also significantly suppress RYR 
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activity 58. Suppression of SERCA is normally associated with smaller systolic Ca2+ 
releases and poor contractility in failing myocardium. Thus low levels of inhibition may 
not have the significant negative inotropic effects but could significantly suppress 
spontaneous Ca2+ waves and therefore arrhythmias. Data from several groups 64-66 
suggest that a burst of Ca2+-activated SERCA activity in regions of a cell adjacent to a 
region of spontaneous Ca2+ release could locally enhance SR load and increase the 
chance of spontaneous Ca2+ release propagating along the length of the cells. Thus mild 
SERCA inhibition may aid an anti-arrhythmic action through this route.  
 
Studies on a CPVT mouse model and a limited number of human CPVT patients have 
shown that Flecainide (a Na+ channel blocker) can suppress arrhythmias associated with 
RYR dysfunction 67 68. The study suggests that the mode of anti-arrhythmic action is not 
via Na+ channel inhibition, but via an inhibitory effect of flecainide on RYR 69. But this 
interpretation of flecainide’s action on RYR has been challenged by isolated RYR 
studies 70 and in intact cell work 71. Another example of a potential revision of the mode 
of action of a cardiovascular drug is the beta blocker Carvedilol. This drug is a potent 
inhibitor of RYR and may act to suppress arrhythmias through this route 72. Further 
screens of beta-blockers have identified other examples of drugs that suppress RYR 
activity and therefore potentially possess anti-DAD and antiarrhythmic activity 73. Such 
examples indicate the challenges in designing anti-arrhythmic therapy around a single 
target with a single molecule and in assigning mechanism to the observed anti-
arrhythmic effect. However, in a recent publication, derivatives of tetracaine with high 
specificity to RyR were found to effectively suppress arrhythmias in a mouse model of 
CPVT 52 and indicates that drug-based RyR inhibition can have powerful anti-arrhythmic 
effects. 
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Alternative anti-arrhythmic strategies:  
Alternative approaches being considered are for example, inhibition of the NCX. This 
may appear a good strategy since this exchanger provides the major Ca+ activated 
currents(Iti) in DADs 73, 74.  But tonic inhibition of this exchanger will reduce the Ca2+ 
efflux capacity of the myocardium, increase intracellular Ca2+ and SR load and 
potentially increase the probability of pro-arrhythmic Ca2+ release. A second approach 
that may indirectly be anti-arrhythmic is to use novel drugs designed to stimulate the 
sarcolemmal Na+/K+ pump/antiporter (NKA) 75. These are designed to restore the 
intracellular Na+ concentration and in doing so, may reduce cellular Ca2+ load via NCX, 
SR load and associated pro-arrhythmic SR Ca2+-leak.  
 
 
  In summary, pharmacological strategies that specifically address abnormal SR Ca+ 
leak are at early stages of development but hold great promise as a means of providing 
novel anti-arrhythmic therapeutic options for a range of cardiac pathologies with 
associated high risk of sudden arrhythmic cardiac death. 
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FIGURE LEGENDS 
 
Figure 1 - Simple diagram of the excitation-contraction coupling system in the 
cardiac cell.  During the action potential Ca
2+
 enters the cell as a rapid influx followed by 
a maintained component of the slow inward Ca2+ current (Thick arrow).  The rapid influx 
of Ca
2+2+
 via the T tubules is thought to induce release of Ca
2+
 from a release 
compartment  in the SR, by triggering opening of Ca
2+
 channels via binding 
sites(sensors) on RYR protein.   Relaxation follows when the cytosolic Ca2+ is 
sequestered again in an uptake compartment of the SR (SERCA pump, green boxes) 
and partly extruded through the cell membrane by the Na
+
/Ca
++
 exchanger (NCX). The 
process of  NCX is electrogenic so that Ca
2+
 extrusion through NCX leads to a 
depolarizing current. From Ter Keurs and Boyden, Physiol Review, 2007 76. 
 
Figure 2.  Representative confocal line-scan images show spontaneous 
Ca
2+
release events (SCaEs) in wild-type (WT) and R33Q (CPVT mutation in CASQ) 
cells in the presence of isoproterenol. Black arrows indicate field stimulations. 
Spontaneous Ca events(SCaEs) in WT myocytes were usually due to a cell-wide wave 
that was initiated at 1 site (red arrow). SCaEs in diseased R33Q cells varied. Often, 
fragmented spontaneous Ca
2+
 waves occurred and slowly propagated (cells 1 and 2), 
and wavelets and Ca
2+
 sparks occurred before Ca
2+
 transients resume the diastolic 
level. From  Liu N et al. Circulation Research 2013;113:142-152 77.  
 
Figure 3. Action potentials recordings in a R33Q mouse cells in the presence of 
isoproterenol at 1- to 3-Hz pacing. Early afterdepolarizations occurred at lower pacing 
frequency; diverse patterns of action potential were shown in all pacing frequencies. 
Bottom, The enlarged membrane oscillations occurring between stimulated beats. 
From Liu N et al. Circulation Research 2013;113:142-152 77. 
 
 
Figure 4-Schematic diagram of a t‐tubule and associated junctional SR. Microfolds 
in t‐tubule are depicted based on recent findings. Different arrangements of Ca
2+
 cycling 
proteins and sodium channels are depicted along the t‐tubule. Regions highlighted by 
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the dashed boxes are presented at higher magnification in C and D. Note that differential 
shading of the interstitial space within the t‐tubule and the cytoplasm within the dyadic 
cleft indicates local differences in ionic concentrations within these spaces due to their 
diffusional isolation from the bulk interstitial space and cytoplasm, respectively. B, results 
from Duolink assays (PLAs) show close association of nNaV isoform NaV1.6 with both 
RYR2 and NCX throughout myocytes, consistent with enrichment of nNaVs in t‐tubules. 
In contrast, PLA signal corresponding to association between cNaV (NaV1.5) and RYR2 
is only observed at the periphery of the cell, consistent with cNaV localization at the 
lateral membrane. Adapted from Radwański et al. 2016, 
doi:10.1016/j.jacbts.2016.04.004, Creative Commons Attribution-NonCommercial-No 
Derivatives License (CC BY NC ND). C, higher magnification views of regions from A 
showing two possible scenarios of nNaV localization within t‐tubules. Left, case 1, very 
close association between nNaVs and RYRs, which is consistent with PLA results. A 
cNaV is depicted faded since experimental results including PLA results argue against 
cNaV enrichment in t‐tubules. Right, case 2, nNaVs localized to t‐tubules but not very 
closely associated with RYRs, which is not consistent with PLA results. D, higher 
magnification view of region from A showing cNaV (NaV1.5) localization at the lateral 
membrane. From Veeraraghavan et al, The Journal of Physiology, © 2017 The 
Physiological Society. 37 Reproduced by permission of John Wiley and Sons, Inc. 
 
Figure 5- JTV519(K201) suppresses cell wide Ca waves in Purkinje cells from the 
infarcted heart A, Graph showing the incidence of cell wide Ca2+ waves in Normal Zone 
Purkinje Cells(NZPCs) and Infarct Zone Purkinjes (IZPCs) in the absence and presence 
of JTV519 (K201) 1 µmol/L (gray bar). B, Ca event rate, spatial extent, and amplitude in 
IZPCs in the absence and presence of JTV519 (K201) (gray bars). Total number of 
events used is shown in parentheses. From Hirose M et al. Circ Arrhythm Electrophysiol 
2008;1:387-395 8. 
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